Jianmin Group released its 2026 interim report, with net profit attributable to the parent company of 177 million yuan, a decrease of 19.68% compared with the same period last year. The company's total operating revenue was 1.611 billion yuan, down 10.72% year-on-year; net cash inflow from operating activities was 120 million yuan, up 116.27% year-on-year. The latest asset-liability ratio was 40.04%, gross margin was 62.48%, ROE was 6.57%, and diluted earnings per share was 1.17 yuan.
Jianmin Pharmaceutical Group Co LtdNet profit fell 19.68% year-on-year in the interim report.
